Market-Moving News for July 12th
$FAST
$IMMP
$ZAPP
RETAIL: Building Materials
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 12/15/2025 | $52.00 | Hold → Buy | Jefferies | |
| 11/13/2025 | Underperform → Peer Perform | Wolfe Research | ||
| 11/12/2025 | $38.00 | Underperform | Bernstein | |
| 10/8/2025 | $49.00 | Equal Weight | Barclays | |
| 8/21/2025 | Neutral | Northcoast | ||
| 8/7/2025 | $55.00 | Neutral → Outperform | Robert W. Baird | |
| 4/3/2025 | Underperform → Peer Perform | Wolfe Research | ||
| 3/10/2025 | Mkt Perform → Outperform | William Blair |
10-K - FASTENAL CO (0000815556) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
8-K - FASTENAL CO (0000815556) (Filer)
The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain on track for the first quarter and the third quarter of CY2026, respectively SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has achieved 50% of the patient enrolment target in the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc.,
Media Release Entered into strategic collaboration with Dr. Reddy's for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater ChinaIn January 2026, Immutep received ~A$30 million upfront payment from Dr. Reddy's and is eligible to receive up to ~A$528 million in potential milestones, plus royalties on commercial sales of eftiStrong operational progress reported for TACTI-004 (KEYNOTE-F91) Phase III trial evaluating efti in first line non-small cell lung cancer (1L NSCLC), with completion of the futility analysis on track for the first quarter of CY2026Data from INSIGHT-003 at ESMO Congress 2025 show combination of efti with KEYTRUDA®
Fastenal Company (NASDAQ:FAST) ('Fastenal,' 'we,' 'our,' or 'us'), a leader in the wholesale distribution of industrial and construction supplies, today announced its financial results for the quarter and year ended December 31, 2025. Except for share and per share information, or as otherwise noted below, dollar amounts are stated in millions. All historical common stock share and per share information and stockholders' equity balances for all periods presented in this release, including the financial statements attached to this release, have been retroactively adjusted to reflect a two-for-one stock split effective at the close of business on May 21, 2025. Percentage and dollar calculatio
4/A - FASTENAL CO (0000815556) (Issuer)
4 - FASTENAL CO (0000815556) (Issuer)
4/A - FASTENAL CO (0000815556) (Issuer)
Jefferies upgraded Fastenal from Hold to Buy and set a new price target of $52.00
Wolfe Research upgraded Fastenal from Underperform to Peer Perform
Bernstein initiated coverage of Fastenal with a rating of Underperform and set a new price target of $38.00
4/A - FASTENAL CO (0000815556) (Issuer)
4 - FASTENAL CO (0000815556) (Issuer)
4 - FASTENAL CO (0000815556) (Issuer)
Fastenal Company (NASDAQ:FAST) ('Fastenal,' 'we,' 'our,' or 'us'), a leader in the wholesale distribution of industrial and construction supplies, today announced its financial results for the quarter and year ended December 31, 2025. Except for share and per share information, or as otherwise noted below, dollar amounts are stated in millions. All historical common stock share and per share information and stockholders' equity balances for all periods presented in this release, including the financial statements attached to this release, have been retroactively adjusted to reflect a two-for-one stock split effective at the close of business on May 21, 2025. Percentage and dollar calculatio
Fastenal Company (NASDAQ:FAST) ('Fastenal,' 'we,' 'our,' or 'us') reported its board of directors declared a dividend of $0.24 per share to be paid in cash on February 26, 2026 to shareholders of record at the close of business on January 29, 2026. Except for share and per share information, dollar amounts are stated in millions. We began paying annual dividends in 1991, semi-annual dividends in 2003, and then expanded to quarterly dividends in 2011. In addition to these regular dividend payments, we have previously paid special one-time dividends in December 2008, December 2012, December 2020, and December 2023. Our board of directors currently intends to continue paying quarterly divide
Fastenal Company (NASDAQ:FAST) ('Fastenal,' 'we,' 'our,' or 'us') announced the date and time for its conference call to review 2025 annual and fourth quarter results, as well as current operations. The conference call will be broadcast live over the Internet on Tuesday, January 20, 2026, at 9:00 a.m. central time. The conference call will be held on Tuesday, January 20, 2026, since Monday, January 19, 2026, is a U.S. federal holiday. To access the call, please visit the following Web address: https://investor.fastenal.com/events.cfm Our conference call presentation (which includes information, supplemental to that contained in our earnings announcement, regarding results for the quar
Fastenal Company (NASDAQ:FAST) (the 'Company' or 'Fastenal') announced today that Daniel L. Florness communicated to the Board of Directors on December 19, 2025 his decision to step out of his role as Chief Executive Officer (CEO) of Fastenal on July 16, 2026. On December 19, 2025, Fastenal's Board appointed Jeffery M. Watts, Fastenal's current President and Chief Sales Officer, to succeed Mr. Florness as Fastenal's CEO effective as of July 16, 2026. "The Board of Directors would like to recognize Dan for his impressive 30 years of service to Fastenal and commend him on the shareholder value he has helped create while CEO over the past 10 years," said Scott Satterlee, Fastenal's Board Cha
LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) ("Zapp EV" or the "Company"), owner of "Zapp", the British electric vehicle brand on a mission to revolutionise personal urban mobility, today announced it has appointed Michael Grant Zapp Limited as its first authorised reseller in Ireland, based in Dublin. Mr. Michael Grant brings more than 40 years of experience in automotive retail businesses to this newly-formed venture dedicated to the sale and support of electric vehicles. David McIntyre, Chief Operating Officer of Zapp EV, said: "We are excited to start working with our first Irish authorised reseller following recent European homologatio
LONDON, March 31, 2025 (GLOBE NEWSWIRE) -- Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) ("Zapp EV" or the "Company"), owner of "Zapp", the British electric vehicle brand on a mission to revolutionise personal urban mobility, today announced it has appointed Green Mopeds Ltd. ("Green Mopeds") as its first authorised reseller of Zapp's urban electric motorcycle, i300, throughout Great Britain. Customers will be able to see i300 on display and arrange for test-rides from the Green Mopeds location in West London. In addition, Green Mopeds will provide delivery and after-sales support utilising Zapp's proprietary drop-ship-direct-to-customer premium service model. Zapp anticipa
SC 13G/A - FASTENAL CO (0000815556) (Subject)
SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)
SC 13G/A - FASTENAL CO (0000815556) (Subject)